Spiro[5.5]undecane M2 Inhibitors Overcoming Amantadine Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-viral agents targeting the M2 protein of influenza A virus, such as amantadine and rimantadine, face significant resistance issues due to mutations in the M2 protein, limiting their effectiveness in treating influenza infections.
Innovation Solution
Development of compounds with the formula (I), which include various substituents and structures that can interact with the M2 proton channel, potentially offering alternative inhibition mechanisms to overcome resistance mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amantadine and rimantadine are used to block the M2 channel, then anti-viral activity is achieved, but resistance develops due to mutations in the M2 protein
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of M2 channel inhibitors. The compounds of formula (I) feature a spiro[5.5]undecane core with specific substituents (R1-R7, Y, Z) that alter the molecular parameters compared to amantadine and rimantadine. This structural parameter change allows the compounds to maintain binding affinity for the M2 channel even when resistance mutations (such as S31N, V27A) are present in the viral protein, thereby overcoming the adaptability issue of viral resistance while preserving anti-viral effectiveness.
2Adaptability or versatility
If BL-1743 is used as an alternative inhibitor, then novel structure is introduced, but resistance spectra overlap with amantadine
Solution Approach 1:
The patent employs composite material principles by creating compounds that combine the spiro[5.5]undecane structural framework with specific functional groups (amino, imidazolyl, hydroxyl substituents). This composite structural approach produces a molecule with novel properties that differ from both amantadine and BL-1743. The specific combination of structural elements in formula (I) creates a unique binding profile against the M2 channel that does not overlap with the resistance spectra of previous inhibitors, thereby achieving both novelty and reliable anti-viral activity.
Data Source
AI summary
Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein.